Drug Profile
SNEC 2
Latest Information Update: 25 Jul 2007
Price :
$50
*
At a glance
- Originator Lundbeck Research USA
- Class Antidepressants
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 19 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
- 08 Feb 2002 Phase-I clinical trials for Depression in USA (Unknown route)